Publications by authors named "D S Buelga"
Article Synopsis
- - This study created a pharmacokinetic model to analyze how lamotrigine (LTG) behaves in the bodies of Spanish and German epilepsy patients based on data from 600 individuals and 1699 plasma drug samples.
- - The final model revealed that factors like total body weight and the presence of other medications (like valproic acid or carbamazepine) significantly affect LTG clearance rates, with comedication modifying the average clearance by over 40%.
- - While this model can help doctors set initial dosages, it still shows around 30% variability in individual responses, highlighting the importance of monitoring LTG plasma levels for accurate dosage adjustments.
Objective: To develop and a priori validate a methotrexate population pharmacokinetic model in children with acute lymphoblastic leukaemia (ALL), receiving high-dose methotrexate followed by folinic acid rescue, identifying the covariates that could explain part of the pharmacokinetic variability of methotrexate.
Methods: The study was carried out in 49 children (aged 6 months to 17 years) who received high-dose methotrexate (3 g/m(2) per course) in long-term treatment. In an index group (37 individuals; 1236 methotrexate plasma concentrations), a population pharmacokinetic model was developed using a nonlinear mixed-effects model.
This study determines vancomycin (VAN) population pharmacokinetics (PK) in adult patients with hematological malignancies. VAN serum concentration data (n = 1,004) from therapeutic drug monitoring were collected retrospectively from 215 patients. A one-compartment PK model was selected.
View Article and Find Full Text PDFThe population kinetics of tobramycin were studied in 140 neonates (100/40 patients for the index/validation groups, respectively) of 30 to 42 weeks' gestational age and 0.8 to 4.25 kg current body weight in their first 2 weeks of life, undergoing routine therapeutic drug monitoring of their tobramycin serum levels.
View Article and Find Full Text PDFObjective: A population analysis of the kinetics of valproic acid (VPA) in children with epilepsy was performed in order to characterize the covariates which influence VPA clearance (CL).
Methods: A total of 770 steady-state serum concentration samples was analysed. These were collected during VPA therapy from 255 children, aged 0.